We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

Fund managers haven’t disclosed any holdings of CARM yet.

CARM Hedge Fund Activity: Q1 2026 in Review

3 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2026, worth a combined $47.9K — down 28% from $67K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CARM and 1 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Golden State Equity Partners, opening a new position worth an estimated $6. The largest seller was XTX Topco, exiting entirely with an estimated $1.72K sold.

  • 3 institutional investors held Carisma Therapeutics (CARM) as of Q1 2026, down from 7 in Q4 2025.
  • Funds reported $47.9K of Carisma Therapeutics stock for Q1 2026, down 28% quarter-over-quarter.
  • 1 fund opened new Carisma Therapeutics positions in Q1 2026 and 4 closed out, a net change of -3 holders.
  • The largest Carisma Therapeutics buyer in Q1 2026 was Golden State Equity Partners, an estimated $6 added.
  • The largest Carisma Therapeutics seller in Q1 2026 was XTX Topco, an estimated $1.72K sold.

Based on aggregated 13F filings for Q1 2026.